The US Department of Agriculture approved the genetically modified purple tomato to extend its shelf life and boost nutritional quality almost 15 years after its development.
According to biochemist Cathie Martin, she and her colleagues at Norfolk Plant Scientists (NPS) have been experimenting with pigment production in flowering plants for over two decades, and they've spent almost 15 months developing the purple tomato.
The NPS has been focusing on anthocyanins, the antioxidant-rich pigments that give blackberries and blueberries their signature shades.
Domesticated tomatoes already have genes to produce anthocyanins, but they are not 'turned on.' By carefully adding two genes, the tomatoes and juice become a rich source of antioxidants, because purple pigments are made in the whole tomato, not just the skins.
While there are already some purple-skinned tomatoes, their pigments mostly stop at the outer layers and don't accumulate in the fruit itself.
The NPS also emphasized that there is increasing evidence to show that antioxidants work much better when consumed within foods.
The USDA Animal and Plant Health Inspection Service (APHIS) reported that the tomato was modified to alter its color and enhance its nutritional quality, adding that the plant is unlikely to pose an increased plant pest risk compared to other cultivated tomatoes.
Nathan Pumplin, the CEO of NPS' US-based commercial business, said they are optimistic that they can begin limited distribution of purple tomatoes in the US by 2023.


Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast
New Zealand Labour Backs India Free Trade Deal, Boosting Chances of Parliamentary Approval
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some
Meta Expands AI Training With Employee Activity Tracking Tools
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 



